Literature DB >> 7593641

Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.

P deS Senanayake1, J Denker, E L Bravo, R M Graham.   

Abstract

Neuropeptide Y (NPY) levels are increased in plasma and tumors of patients with pheochromocytoma. The present study was designed to evaluate plasma and tissue NPY levels simultaneously as well as to study its release and expression in patients with either adrenal or extraadrenal pheochromocytomas. Plasma NPY levels were higher (P < 0.01) in patients with adrenal tumors than in matched normal subjects and patients with extraadrenal tumors. NPY levels were also higher (P < 0.05) in adrenal than in extraadrenal tumors. Bioactive NPY (1-36) was the predominant form in plasma and tumors of patients with adrenal pheochromocytomas. In contrast, patients with extraadrenal pheochromocytomas had an abundance of NPY fragments. NPY mRNA was abundant in 11 of 13 adrenal tumors but in only 1 of 6 extraadrenal tumors. Moreover, NPY was coreleased with NE with manipulation of adrenal but not extraadrenal tumors. These findings indicate that increased NPY gene expression in adrenal pheochromocytomas accounts for the greater biosynthesis and storage of NPY in these tumors and that increased release of NPY results in elevated plasma NPY. Factors regulating NPY gene expression in pheochromocytoma and the role of NPY in the clinical manifestations of the disease remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593641      PMCID: PMC185905          DOI: 10.1172/JCI118310

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade.

Authors:  J M Lundberg; K Tatemoto
Journal:  Acta Physiol Scand       Date:  1982-12

3.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

4.  Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumour content of insulin and proinsulin-like components and the histological and ultrastructural appearance.

Authors:  W Creutzfeldt; R Arnold; C Creutzfeldt; U Deuticke; H Frerichs; N S Track
Journal:  Diabetologia       Date:  1973-06       Impact factor: 10.122

5.  Radioimmunoassay of neuropeptide Y.

Authors:  J M Allen; J C Yeats; T E Adrian; S R Bloom
Journal:  Regul Pept       Date:  1984-01

6.  Neuropeptide Y (NPY) in PC12 phaeochromocytoma cultures: responses to dexamethasone and nerve growth factor.

Authors:  J M Allen; A S Tischler; Y C Lee; S R Bloom
Journal:  Neurosci Lett       Date:  1984-05-18       Impact factor: 3.046

7.  Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue.

Authors:  R Corder; P C Emson; P J Lowry
Journal:  Biochem J       Date:  1984-05-01       Impact factor: 3.857

8.  Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas.

Authors:  T E Adrian; J M Allen; G Terenghi; A J Bacarese-Hamilton; M J Brown; J M Polak; S R Bloom
Journal:  Lancet       Date:  1983-09-03       Impact factor: 79.321

9.  Angiotensin-II mediates norepinephrine and neuropeptide-Y secretion in a human pheochromocytoma.

Authors:  E Grouzmann; P Werffeli-George; M Fathi; M Burnier; B Waeber; G Waeber
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  11 in total

Review 1.  Adrenal medulla.

Authors:  J D Greifenkamp; D J DiPette
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

2.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

Review 3.  Expression of trophic peptides and their receptors in chromaffin cells and pheochromocytoma.

Authors:  Erwan Thouennon; Alice Pierre; Laurent Yon; Youssef Anouar
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

4.  Hypertension in pheochromocytoma: characteristics and treatment.

Authors:  Samuel M Zuber; Vitaly Kantorovich; Karel Pacak
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

5.  Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.

Authors:  Susana Galli; Arlene Naranjo; Collin Van Ryn; Jason U Tilan; Emily Trinh; Chao Yang; Jessica Tsuei; Sung-Hyeok Hong; Hongkun Wang; Ewa Izycka-Swieszewska; Yi-Chien Lee; Olga C Rodriguez; Chris Albanese; Joanna Kitlinska
Journal:  Am J Pathol       Date:  2016-10-12       Impact factor: 4.307

6.  Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.

Authors:  Jason U Tilan; Mark Krailo; Donald A Barkauskas; Susana Galli; Haifa Mtaweh; Jessica Long; Hongkun Wang; Kirsten Hawkins; Congyi Lu; Dima Jeha; Ewa Izycka-Swieszewska; Elizabeth R Lawlor; Jeffrey A Toretsky; Joanna B Kitlinska
Journal:  Cancer       Date:  2014-11-11       Impact factor: 6.860

7.  The arcuate nucleus and neuropeptide Y contribute to the antitumorigenic effect of calorie restriction.

Authors:  Robin K Minor; Miguel López; Caitlin M Younts; Bruce Jones; Kevin J Pearson; Robert Michael Anson; Carlos Diéguez; Rafael de Cabo
Journal:  Aging Cell       Date:  2011-04-05       Impact factor: 9.304

8.  Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.

Authors:  Susannah Cleary; Jacqueline K Phillips; Thanh-Truc Huynh; Karel Pacak; Abdel G Elkahloun; Jennifer Barb; Robert A Worrell; David S Goldstein; Graeme Eisenhofer
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

Review 9.  Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2015-10-26       Impact factor: 3.286

Review 10.  Pheochromocytomas and secreting paragangliomas.

Authors:  Pierre-François Plouin; Anne-Paule Gimenez-Roqueplo
Journal:  Orphanet J Rare Dis       Date:  2006-12-08       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.